Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 May;22(3):299-304.
doi: 10.1007/s10741-017-9617-4.

DPP4 inhibitors and cardiovascular outcomes: safety on heart failure

Chang Xia  1   2 , Aditya Goud  2 , Jason D'Souza  3 , CHanukya Dahagam  4 , Xiaoquan Rao  2 , Sanjay Rajagopalan  2 , Jixin Zhong  5
Affiliations
Review

DPP4 inhibitors and cardiovascular outcomes: safety on heart failure

Chang Xia et al. Heart Fail Rev. 2017 May.

Abstract

Diabetes is an important risk factor for cardiovascular disease. However, clinical data suggests intensive glycemic control significantly increase rather than decrease cardiovascular mortality, which is largely due to the fact that a majority of oral anti-diabetic drugs have adverse cardiovascular effect. There are several large-scale clinical trials evaluating the cardiovascular safety of DPP4 inhibitors, a novel class of oral anti-diabetic medications, which have been recently completed. They were proven to be safe with regard to cardiovascular outcomes. However, concerns on the safety of heart failure have been raised as the SAVOR-TIMI 53 trial reported a 27% increase in the risk for heart failure hospitalization in diabetic patients treated with DPP4 inhibitor saxagliptin. In this review, we will discuss recent advances in the heart failure effects of DPP4 inhibition and GLP-1 agonism.

Trial registration: ClinicalTrials.gov NCT01107886.

Keywords: Cardiovascular outcomes; DPP4; Heart failure; Incretin.

PubMed Disclaimer

References

    1. International Diabetes Federation. IDF Diabetes Atlas. 7. International Diabetes Federation; Brussels: 2015.
    1. Chen X-W, He Z-X, Zhou Z-W, et al. Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus. Clin Exp Pharmacol Physiol. 2015;42:999–1024. doi: 10.1111/1440-1681.12455. - DOI - PubMed
    1. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetologia. 2012;55:1577–96. doi: 10.1007/s00125-012-2534-0. - DOI - PubMed
    1. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355:2427–43. doi: 10.1056/NEJMoa066224. - DOI - PubMed
    1. Scirica BM, Braunwald E, Raz I, et al. Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial. Circulation. 2015;132:e198. doi: 10.1161/CIR.0000000000000330. - DOI - PubMed

Publication types

MeSH terms

Substances

Associated data